Australia's Rhythm Biosciences soars on cancer tech expansion

Rhythm Biosciences

14/12/2021 03:52

** Shares of cancer diagnostic co  RHY.AX  soar as much as
13.8% to A$1.9, their highest since Nov.30
    ** Says its initial bowel cancer product, ColoSTAT, is
believed to possess multi-cancer detection properties targeting
five additional cancer diagnostics for platform technology
expansion  urn:newsml:reuters.com:*:nASX1cbgkL
    ** Says the initial five additional cancers targeted for
detection include breast, cervical, lung, gastric and pancreatic
    ** Says RHY has identified a number of additional cancer  
target markets to form a part of R&D program that ultimately
will help commercialize ColoSTAT 
    ** Adds that primary focus of co remains on launching
ColoSTAT in CY2022
    ** Stock set for its biggest intraday gain since Nov. 30
    ** Stock has risen 91.4% this year as of last close

 (Reporting by Roushni Nair in Bangalore)
 ((Roushni.Nair@thomsonreuters.com))